Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Avelas Biosciences

Request full access

Innovative intraoperative cancer detection with AVB 620, enhancing surgical precision and patient outcomes

San Diego, United StatesFounded 2008Biotech & Life Sciences

About Avelas Biosciences

Avelas Biosciences is a clinical-stage oncology company dedicated to improving cancer surgery outcomes through its lead product, AVB 620. AVB 620 is a novel drug-device combination designed to detect cancer in real-time during surgery, allowing surgeons to identify and remove cancerous tissue more accurately. This technology aims to become a standard part of care in various cancer surgeries, including ovarian, colorectal, head and neck, lung, and melanoma. Avelas operates in the medical and healthcare market, primarily serving surgeons and hospitals. The company generates revenue through the development and potential future sales of its innovative cancer detection products.

Source: Dealroom company data

At a glance

Status
Operational
Employees
2
Open positions
None listed
Dealroom signal
58.3/100
Industry
Health
Sub-industry
BioTechnology, Health Platform
Sector
Biotechnology, Oncology, Surgery, Non-Invasive medical devices and treatments, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
B2B

Funding history

6 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
OtherOther financing Jun 2019 $0 — Undisclosed —
SERIES C✓Equity / VC Aug 2016 $20M $80M Pharmstandard —
Showing the latest 2 of 6 recorded eventsBook a demo for the full funding history →

Growth signals

Avelas Biosciences website traffic

Latest recorded traffic for Avelas Biosciences is 400 monthly website visits, up 90.5% over the last three months. Avelas Biosciences's team declined 33.3% over the past year.

Latest monthly visits400 3-month web change+90.5% 1-year team growth-33.3%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Avelas Biosciences in the San Diego ecosystem

Live from Dealroom

The Avelas Biosciences office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Avalon Ventures
  • WuXi AppTec
  • Torrey Pines Investment
  • WuXi Healthcare Ventures

Series B and later1 investor entered at this stage

  • Pharmstandard

Other known investors1 additional known investor

  • University of California, San Diego
Team profiled 9 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Avelas Biosciences on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Avelas Biosciences’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.